All Stories

  1. TNF receptor activation through pre-assembly and tonic signaling

    Article • Trends Open, June 2026, Elsevier

    Dr Legembre Patrick

  2. Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders

    Article • Arabian archaeology and epigraphy, May 2025, Elsevier

    Dr Legembre Patrick

  3. CD95/Fas stoichiometry in future precision medicine

    Article • Cell Death and Differentiation, April 2025, Springer Science + Business Media

    Dr Legembre Patrick

  4. Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models

    Article • Journal of Clinical Investigation, February 2024, American Society for Clinical Investigation

    Dr Legembre Patrick

  5. Membrane‐bound CD95 ligand modulates CD19‐mediated B cell receptor signaling and EBV activation

    Article • Journal of Medical Virology, February 2024, Wiley

    Dr Legembre Patrick

  6. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, November 2023, Elsevier

    Dr Legembre Patrick

  7. CD95L concatemers highlight different stoichiometries of CD95‐mediated apoptotic and non‐apoptotic pathways

    Article • European Journal of Immunology, October 2023, Wiley

    Dr Legembre Patrick

  8. CD95L concatemers highlight difference in the manner CD95-mediated apoptotic and non-apoptotic pathways are triggered

    Article • June 2023, Cold Spring Harbor Laboratory Press

    Dr Legembre Patrick

  9. Ambivalent role of FasL in murine acute graft-versus-host-disease

    Article • Journal of Leukocyte Biology, April 2023, Oxford University Press (OUP)

    Dr Legembre Patrick

  10. MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways

    Article • Cell Death and Disease, October 2022, Springer Science + Business Media

    Dr Legembre Patrick

  11. Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network

    Article • Biomolecules, June 2022, MDPI AG

    Dr Legembre Patrick

  12. Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors

    Article • Cells, April 2022, MDPI AG

    Dr Legembre Patrick

  13. Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii

    Article • Microbes and Infection, March 2022, Elsevier

    Dr Legembre Patrick

  14. Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity

    Article • Proceedings of the National Academy of Sciences, December 2021, Proceedings of the National Academy of Sciences

    Dr Legembre Patrick

  15. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, December 2021, Elsevier

    Dr Legembre Patrick

  16. CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

    Article • iScience, December 2021, Elsevier

    Dr Legembre Patrick

  17. CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

    Article • iScience, November 2021, Elsevier

    Dr Legembre Patrick

  18. Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipig

    Article • Journal of Gynecology Obstetrics and Human Reproduction, September 2021, Elsevier

    Dr Legembre Patrick

  19. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis

    Article • Science Translational Medicine, June 2021, American Association for the Advancement of Science

    Dr Legembre Patrick

  20. Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation

    Article • Frontiers in Immunology, September 2020, Frontiers

    Dr Legembre Patrick

  21. CD95 Structure, Aggregation and Cell Signaling

    Article • Frontiers in Cell and Developmental Biology, May 2020, Frontiers

    Dr Legembre Patrick

  22. Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer

    Article • Cancer Research, February 2020, American Association for Cancer Research (AACR)

    Dr Legembre Patrick

  23. Editor's Note: Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP

    Article • Cancer Research, January 2020, American Association for Cancer Research (AACR)

    Dr Legembre Patrick

  24. The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis

    Article • January 2020, Springer Science + Business Media

    Dr Legembre Patrick

  25. Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction

    Article • Bioorganic & Medicinal Chemistry Letters, November 2019, Elsevier

    Dr Legembre Patrick

  26. Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells

    Article • Journal of Medicinal Chemistry, October 2019, American Chemical Society (ACS)

    Dr Legembre Patrick

  27. Correction: The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway

    Article • PLoS Biology, October 2019, PLOS

    Dr Legembre Patrick

  28. Investigation of Phospholipase Cγ1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors

    Article • International Journal of Molecular Sciences, September 2019, MDPI AG

    Dr Legembre Patrick

  29. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer

    Article • Molecular Cancer Research, September 2019, American Association for Cancer Research (AACR)

    Dr Legembre Patrick

  30. HIV protease inhibitors and autoimmunity: An odd, but promising idea

    Article • Autoimmunity Reviews, August 2019, Elsevier

    Dr Legembre Patrick

  31. Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis

    Article • Bioorganic & Medicinal Chemistry Letters, August 2019, Elsevier

    Dr Legembre Patrick

  32. CD95/Fas and metastatic disease: What does not kill you makes you stronger

    Article • Seminars in Cancer Biology, June 2019, Elsevier

    Dr Legembre Patrick

  33. Staphylococcus aureus induces DNA damage in host cell

    Article • Scientific Reports, May 2019, Springer Science + Business Media

    Dr Legembre Patrick

  34. An insight into the role of the death receptor CD95 throughout pregnancy: Guardian, facilitator, or foe

    Article • Birth Defects Research, January 2019, Wiley

    Dr Legembre Patrick

  35. Chemical Composition, Antioxidant, and Anticancer Effect of Ruta chalepensis’s Extracts against Human Leukemic Cells

    Article • Phytothérapie, December 2018, Lavoisier

    Dr Legembre Patrick

  36. Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation

    Article • Nature Chemical Biology, November 2018, Springer Science + Business Media

    Dr Legembre Patrick

  37. Ovarian Cancer Immunity

    Article • September 2018, Oxford University Press (OUP)

    Dr Legembre Patrick

  38. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

    Article • Nature Communications, August 2018, Springer Science + Business Media

    Dr Legembre Patrick

  39. Tumor analysis: freeze–thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells

    Article • BMC Research Notes, June 2018, Springer Science + Business Media

    Dr Legembre Patrick

  40. Nonapoptotic functions of Fas/CD95 in the immune response

    Article • European Journal of Biochemistry, November 2017, Wiley

    Dr Legembre Patrick

  41. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases

    Article • Frontiers in Immunology, September 2017, Frontiers

    Dr Legembre Patrick

  42. Chemical composition, antioxidant, and anticancer effect of Ruta chalepensis’s extracts against human leukemic cells

    Article • Phytothérapie, September 2017, Lavoisier

    Dr Legembre Patrick

  43. FAS (Fas cell surface death receptor)

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, August 2017, INIST-CNRS

    Dr Legembre Patrick

  44. T cell landscape in triple negative breast cancer patients

    Article • The Breast, March 2017, Elsevier

    Dr Legembre Patrick

  45. Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  46. Erratum

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  47. CD95

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  48. CD95 Stimulation with CD95L and DISC Analysis

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  49. Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  50. Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  51. Atypical Immune Functions of CD95/CD95L

    Article • January 2017, Springer Science + Business Media

    Dr Legembre Patrick

  52. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress

    Article • Oncotarget, December 2016, Impact Journals, LLC

    Dr Legembre Patrick

  53. Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?

    Article • Annals of Translational Medicine, December 2016, AME Publishing Company

    Dr Legembre Patrick

  54. How mTOR inhibitors show some success in clinical trials

    Article • Recent Patents on Anti-Cancer Drug Discovery, August 2016, Bentham Science Publishers

    Dr Legembre Patrick

  55. Cyaneodimycin, a Bioactive Compound Isolated from the Culture ofStreptomyces cyaneofuscatusAssociated withLichina confinis

    Article • European Journal of Organic Chemistry, July 2016, Wiley

    Dr Legembre Patrick

  56. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice

    Article • Immunity, July 2016, Elsevier

    Dr Legembre Patrick

  57. The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca2+ flux from the endoplasmic reticulum to mitochondria

    Article • Cell Death and Differentiation, July 2016, Springer Science + Business Media

    Dr Legembre Patrick

  58. The cleaved FAS ligand activates the Na+/H+ exchanger NHE1 through Akt/ROCK1 to stimulate cell motility

    Article • Scientific Reports, June 2016, Springer Science + Business Media

    Dr Legembre Patrick

  59. Sphingolipids modulate the epithelial–mesenchymal transition in cancer

    Article • Cell Death Discovery, October 2015, Nature

    Dr Legembre Patrick

  60. Meet Our Editorial Board Member:

    Article • Recent Patents on Anti-Cancer Drug Discovery, September 2015, Bentham Science Publishers

    Dr Legembre Patrick

  61. Chemotherapy with ceramide in TNBC

    Article • Oncoscience, August 2015, Impact Journals, LLC

    Dr Legembre Patrick

  62. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells

    Article • Journal of Medicinal Chemistry, August 2015, American Chemical Society (ACS)

    Dr Legembre Patrick

  63. The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis

    Article • August 2014, Springer Science + Business Media

    Dr Legembre Patrick

  64. The CD95/CD95L signaling pathway: A role in carcinogenesis

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, August 2014, Elsevier

    Dr Legembre Patrick

  65. Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility

    Article • Oncogene, March 2014, Springer Science + Business Media

    Dr Legembre Patrick

  66. CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer

    Article • Cancer Research, September 2013, American Association for Cancer Research (AACR)

    Dr Legembre Patrick

  67. Staphylococcus aureus-Induced G2/M Phase Transition Delay in Host Epithelial Cells Increases Bacterial Infective Efficiency

    Article • PLOS One, May 2013, PLOS

    Dr Legembre Patrick, Dr Vasco Azevedo

  68. Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity

    Article • PLOS One, January 2013, PLOS

    Dr Legembre Patrick

  69. Precise Mapping of the CD95 Pre-Ligand Assembly Domain

    Article • PLOS One, September 2012, PLOS

    Dr Legembre Patrick

  70. Guidelines for the use and interpretation of assays for monitoring autophagy

    Article • Autophagy, April 2012, Taylor & Francis

    Dave Bridges, Professor CIRO ISIDORO, Professor George Perry, Dr Takeshi Noda, Professor Nektarios Tavernarakis, Matthias Gaestel, Dr Francesca Demarchi, Maria Vaccaro, Juan Segura-Aguilar, Leonardo Travassos, Manoj B Menon, Isabelle Dugail, Dr Legembre Patrick, Dr Marc Etienne Poirot, Professor Paula I. Moreira, Executive Director, The Hormel Institute Robert Clarke, Professor Godefridus J Peters, Professor Brigitte Galliot, Professor Luca Scorrano

  71. The CD95 signaling pathway

    Article • Communicative & Integrative Biology, March 2012, Taylor & Francis

    Dr Legembre Patrick

  72. CD95 triggers Orai1-mediated localized Ca2+entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation

    Article • Proceedings of the National Academy of Sciences, November 2011, Proceedings of the National Academy of Sciences

    Dr Legembre Patrick

  73. CD95-mediated cell signaling in cancer: mutations and post-translational modulations

    Article • Cellular and Molecular Life Sciences, November 2011, Springer Science + Business Media

    Dr Legembre Patrick

  74. Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre and Faustino Mollinedo)]

    Article • Recent Patents on Anti-Cancer Drug Discovery, September 2011, Bentham Science Publishers

    Dr Legembre Patrick

  75. Actin-independent exclusion of CD95 by PI3K/AKT signalling: Implications for apoptosis

    Article • European Journal of Immunology, July 2011, Wiley

    Dr Legembre Patrick

  76. Does calcium contribute to the CD95 signaling pathway?

    Article • Anti-Cancer Drugs, July 2011, Wolters Kluwer Health

    Dr Legembre Patrick

  77. The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway

    Article • PLoS Biology, June 2011, PLOS

    Dr Legembre Patrick

  78. S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand–Mediated Apoptosis in Cancer Cells

    Article • Gastroenterology, June 2011, Elsevier

    Dr Legembre Patrick

  79. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells

    Article • European Journal of Cancer, May 2010, Elsevier

    Dr Legembre Patrick

  80. Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?

    Article • Recent Patents on Anti-Cancer Drug Discovery, January 2010, Bentham Science Publishers

    Dr Legembre Patrick

  81. CD95 engagement mediates actin-independent and -dependent apoptotic signals

    Article • Cell Death and Differentiation, August 2009, Springer Science + Business Media

    Dr Legembre Patrick

  82. The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells

    Article • PLOS One, May 2009, PLOS

    Dr Legembre Patrick

  83. An atypical necrotic signal induced by immunosuppressive and anti-viral agents

    Article • Autophagy, April 2009, Taylor & Francis

    Dr Legembre Patrick

  84. Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway

    Article • Molecular Cancer Research, March 2008, American Association for Cancer Research (AACR)

    Dr Legembre Patrick

  85. Rewinding the DISC

    Article • Archivum Immunologiae et Therapiae Experimentalis, February 2008, Springer Science + Business Media

    Dr Legembre Patrick

  86. The HA tag is cleaved and loses immunoreactivity during apoptosis

    Article • Nature Chemical Biology, February 2007, Nature

    Dr Legembre Patrick

  87. Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP

    Article • Cancer Research, January 2007, American Association for Cancer Research (AACR)

    Dr Legembre Patrick

  88. Corrigendum to “Does CD95 have tumor promoting activities?” [Biochim. Biophys. Acta 1755 (2005) 25–36]

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, January 2007, Elsevier

    Dr Legembre Patrick

  89. Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment

    Article • Molecular and Cellular Biology, August 2005, ASM Journals

    Dr Legembre Patrick

  90. Does CD95 have tumor promoting activities?

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, May 2005, Elsevier

    Dr Legembre Patrick

  91. Induction of apoptosis and activation of NF‐κB by CD95 require different signalling thresholds

    Article • EMBO Reports, November 2004, EMBO

    Dr Legembre Patrick

  92. The relevance of NF-?B for CD95 Signaling in Tumor Cells

    Article • Cell Cycle, October 2004, Taylor & Francis

    Dr Legembre Patrick

  93. Identification of SNF1/AMP Kinase-related Kinase as an NF-κB-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness

    Article • Journal of Biological Chemistry, September 2004, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Legembre Patrick

  94. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells

    Article • The EMBO Journal, July 2004, Wiley

    Dr Legembre Patrick

  95. Two CD95 tumor classes with different sensitivities to antitumor drugs

    Article • Proceedings of the National Academy of Sciences, September 2003, Proceedings of the National Academy of Sciences

    Dr Legembre Patrick

  96. Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism

    Article • British Journal of Haematology, March 2003, Wiley

    Dr Christophe F Grosset, Dr Legembre Patrick

  97. Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas

    Article • Cell Death and Differentiation, February 2002, Nature

    Dr Legembre Patrick